rhEPO in hematopoietic stem cell mobilization, transplantation and in-vitro expansion

  • Sven Klaesson


Various hematopoietic growth factors and cytokines are being increasingly studied in the transplant setting. They are used, not only to accelerate haematopoietic recovery after cytopenias but also as mobilizers of stem cells in donors, ex vivo expansion of stem cells and for supportive treatment during infections. All these new factors, alone or in combination, may contribute to improved regimens during transplantation. Bone marrow transplant (BMT) or peripheral blood progenitor stem cells transplant (PBSCT) recipients have in the period following transplantation a frequent need for red blood cell transfusions and, therefore, an increased risk of blood-transmitted infections. The anemia is caused mainly by myelosuppression after high-dose chemotherapy but an impaired erythropoietin (EPO) production and an inappropriate EPO response may also contribute. Since recombinant human erythropoietin (rhEPO) has been established as a treatment for renal anemia it has been of interest whether treatment may be of benefit in the transplantation setting. So far data do not support any transfusional benefits with the use of rhEPO after autologous transplantation. In patients receiving an allograft, especially patients with immune hemolysis after transplantation, rhEPO treatment seems to accelerate erythroid engraftment, increase hemoglobin levels, reduce red blood cell transfusions and shorten time to transfusion independence. However, the optimal dose of rhEPO, the route of administration, the most effective combination with other hematopoietic growth factors, and in which patient populations cost-effective rhEPO therapy is justified are still open questions.


Bone Marrow Transplant Allogeneic Bone Marrow Transplant Recombinant Human Erythropoietin Hematopoietic Growth Factor rhEPO Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abedi MR, Bäckman L, Boström L, Lindbäck B, Ringdén O (1990) Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 6: 121–126PubMedGoogle Scholar
  2. 2.
    Akiyama H, Tanikawa S, Takamoto S, Sakamaki H, Sasaki T, Onozawa Y (1995) Recombinant human erythropoietin (rhEPO) administration to marrow donors. Bone Marrow Transplantation ( BMT) Team. Int J Hematol 62: 145–149Google Scholar
  3. 3.
    Appelbaum FR (1995) Allogeneic marrow transplantation and the use of hematopoietic growth factors. Stem Cells 13: 344–350PubMedCrossRefGoogle Scholar
  4. 4.
    Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M et al (1994) Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 87: 153–161PubMedCrossRefGoogle Scholar
  5. 5.
    Beguin Y, Clemons GK, Oris R, Fillet G (1991) Circulating erythropoietin levels after bone marrow transplantation: inappropiate response to anemia in allogeneic transplants. Blood 77: 868–873PubMedGoogle Scholar
  6. 6.
    Beguin Y, Oris R, Fillet G (1993) Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 11: 285–292PubMedGoogle Scholar
  7. 7.
    Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R (1995) Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 15: 129–134Google Scholar
  8. 8.
    Bruno E, Miller ME, Hoffman R (1989) Interacting cytokines regulate in vitro human megakaryocytopoiesis. Blood 73: 671–677PubMedGoogle Scholar
  9. 9.
    Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG (1994) A randomized study of erythropoietin and granulocyte colony-stimulating factor ( G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 83: 2823–2828Google Scholar
  10. 10.
    Cremieux P, Barrett B, Anderson K, Slavin M (2000) Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 18: 2755–2761PubMedGoogle Scholar
  11. 11.
    Cremieux P, Finkelstein S, Berndt E, Crawford J, Slavin M (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16: 459–472Google Scholar
  12. 12.
    Dessypris EN, Gleaton JH, Amstrong OL (1987) Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 65: 265–269PubMedCrossRefGoogle Scholar
  13. 13.
    Engel H, Kaya E, Bald R, Kolhagen H, Grecu O, Schondorf T, Brenne U, Kurbacher C, Gohring U, Kleine M, Malimann P (1999) Fetal cord blood as an alternative source of hematopoietic progenitor cells. Immunophenotype, maternal cell contamination, and ex vivo expansion. J Hematother 8: 141–155PubMedCrossRefGoogle Scholar
  14. 14.
    Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79: 1987–1994PubMedGoogle Scholar
  15. 15.
    Faulds D, Sorkin EM (1989) Epoetin (recombinant human erythropoietin), a review. Drugs 38: 863–899PubMedCrossRefGoogle Scholar
  16. 16.
    Fujimori Y, Kanamaru A, Saheki K, Mori A, Takatsuka H, Wada H, Okada M, Tamura S, Okamoto T, Takemoto Y, Kakishita E, Nagai K (1998) Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation. Int J Hematol 67: 131–136PubMedCrossRefGoogle Scholar
  17. 17.
    Fujisawa S, Maruta A, Sakai R, Taguchi J, Tomita N, Ogawa K, Kodama F, Takahashi K, Shibayama S, Kobayashi S, Ikuta K, Okubo T (1996) Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 9: 506–508PubMedCrossRefGoogle Scholar
  18. 18.
    Henry D (1997) Haematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors. Ann Oncol 8 (Suppl 3): 57–10CrossRefGoogle Scholar
  19. 19.
    Henry DH (1998) Epoetin alfa and high-dose chemotherapy. Semin Oncol 25 (Suppl 7): 54–57PubMedGoogle Scholar
  20. 20.
    Hod WH (1992) Optimal route of administration of erythropoietin in chronical renal failure patients: intravenous versus subcutaneous. Acta Haematol 87: 16–19Google Scholar
  21. 21.
    Ireland RM, Atkinson KA, Biggs JC (1989) Erythropoietin changes following autologous and allogeneic bone marrow transplantation. Exp Hematol 17: 591Google Scholar
  22. 22.
    Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L (1994) Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 13: 397–402PubMedGoogle Scholar
  23. 23.
    Lazarus HM, Rowe JM (1994) Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation. Blood Rev 8: 169–178PubMedCrossRefGoogle Scholar
  24. 24.
    Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A et al (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84: 3327–3335PubMedGoogle Scholar
  25. 25.
    Link H, Brune T, Hubner G, Diedrich H, Freund M, Stoll M, Peest D, Ebell W, Bettoni C, Oster W et al (1993) Effect of recombinant human erythropoietin after allogenic bone marrow transplantation. Ann Hematol 67: 169–173PubMedCrossRefGoogle Scholar
  26. 26.
    Locatelli F, Zecca M, Beguin Y, Giorgiani G, Ponchio L, De Stefano P, Cazzola M (1993) Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation. Br J Haematol 84: 752–754PubMedCrossRefGoogle Scholar
  27. 27.
    Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P, De Stefano P, Beguin Y, Robustelli della Cuna G, Severi F et al (1994) Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13: 403–410PubMedGoogle Scholar
  28. 28.
    Locatelli F, Zecca M, Ponchio L, Beguin Y, Giorgiani G, Maccario R, Bonetti F, De Stefano P, Cazzola M (1994) Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 14: 929–935PubMedGoogle Scholar
  29. 29.
    Lopez J, Steegmann JL, Perez G, Otero MJ, Berberana M, Camara R, Lamana M, Fernandez Villalta MJ, Fernandez-Ranada JM (1994) Erythropoietin in the treatment of delayed immune hemolysis of a major ABO-incompatible bone marrow transplant. Am J Hematol 45: 237–239PubMedCrossRefGoogle Scholar
  30. 30.
    Lundell B, Mandalam R, Smith A (1999) Clinical scale expansion of cryopreserved small volume whole bone marrow aspirates produces sufficient cells for clinical use. J Hematother 8: 115–127PubMedCrossRefGoogle Scholar
  31. 31.
    McMahon FG, Vargas R, Ryan M et al (1990) Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76: 1718–1722PubMedGoogle Scholar
  32. 32.
    Miller CB, Jones RJ, Zahurak ML, Piantadosi S, Burns WH, Santos GW, Spivak JL (1992) Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 80: 2677–2682PubMedGoogle Scholar
  33. 33.
    Mitus AJ, Antin JH, Rutherford CJ, McGarigle CJ, Goldberg MA (1994) Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood 83: 1952–1957PubMedGoogle Scholar
  34. 34.
    Nemunaitis J (1995) Recombinant hematopoietic growth factors in bone marrow transplantation. Cancer Treat Res 76: 225–248PubMedCrossRefGoogle Scholar
  35. 35.
    Paltiel O, Cournoyer D, Rybka W (1993) Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 33: 418–421PubMedCrossRefGoogle Scholar
  36. 36.
    Pene R, Appelbaum FR, Fisher L, Lilleby K, Nemunaitis J, Storb R, Buckner CD (1993) Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 11: 219–222PubMedGoogle Scholar
  37. 37.
    Pierelli L, Perillo A, Greggi S, Salerno G, Panici P, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G (1999) Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17: 1288–1295PubMedGoogle Scholar
  38. 38.
    Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringdén O (1992) Blood transfusion in marrow graft recipients. Ann Hematol 65: 66–70PubMedCrossRefGoogle Scholar
  39. 39.
    Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S (1997) Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 20: 1105–1107PubMedCrossRefGoogle Scholar
  40. 40.
    Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA (1990) Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76: 2354–2359PubMedGoogle Scholar
  41. 41.
    Sheffield R, Sullivan SD, Saltiel E, Nishimura L (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacotherapy 31: 15–22Google Scholar
  42. 42.
    Spivak JL (1990) Erythropoietin: From bench to bedside. Trans Am Clin Assoc 102: 232–244Google Scholar
  43. 43.
    Spivak JL (1991) Overview of the literature related to Erythropoietin. Excerpta Medica, Amsterdam, NetherlandsGoogle Scholar
  44. 44.
    Steegmann JL, López J, Otero MJ, Lamana ML, de la Camara R, Berberana M, Díaz A, Fernandez-Ranada JM (1992) Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 10: 541–546PubMedGoogle Scholar
  45. 45.
    Stiff P, Chen B, Franklin W, Oldenberg D, Hsi E, Bayer R, Shpall E, Douville J, Mandalam R, Malhotra D, Muller T, Armstrong R, Smith A (2000) Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood 95: 2169–2174PubMedGoogle Scholar
  46. 46.
    Vannucchi AM, Bosi A, Grossi A, Guidi S, Saccardi R, Lombardini L, RossiFerrini P (1992) Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients. Leukemia 6: 215–219Google Scholar
  47. 47.
    Vannucchi AM, Bosi A, Ieri A, Guidi S, Saccardi R, Lombardini L, Linari S, Laszlo D, Longo G, Rossi-Ferrini P (1996) Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 17: 527–531PubMedGoogle Scholar
  48. 48.
    Vannucchi AM, Bosi A, Linari S, Guidi S, Longo G, Lombardini L, Mariani MP, Saccardi R, Laszlo D, Rossi Ferrini P (1997) High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study. Haematologica 82: 53–56Google Scholar
  49. 49.
    Vannucchi AM, Grossi A, Bosi A, Rafanelli D, Statello M, Guidi S, Saccardi R, Rossi-Ferrini P (1993) Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 82: 978–984PubMedGoogle Scholar
  50. 50.
    Winearls CG (1993) Treatment of the anaemia of chronic renal failure with rHuEPO. Erythropoiesis: New Dimensions in the Treatment of Anaemia 4: 3–9Google Scholar
  51. 51.
    Won JH, Cho SD, Park SK, Lee GT, Baick SH, Suh WS, Hong DS, Park HS (2000) Thrombopoietin is synergistic with other cytokines for expansion of cord blood progenitor cells. J Hematother & Stem Cell Research 9: 465–473CrossRefGoogle Scholar
  52. 52.
    York A, Clift RA, Sanders JE, Buckner CD (1992) Recombinant human erythropoietin (rh-Epo) administration to normal marrow donors. Bone Marrow Transplant 10: 415–417PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.B57 Department of Pediatrics, Karolinska InstituteHuddinge University HospitalStockholmSweden

Personalised recommendations